

ORIGINAL

**UNITED STATES OF AMERICA  
NUCLEAR REGULATORY COMMISSION**

**Title:** Briefing on Static Elimination Problems

**Location:** Washington, D. C.

**Date:** Thursday, February 18, 1988

**Pages:** 1 - 36

**Ann Riley & Associates**

*Court Reporters*

1625 I Street, N.W., Suite 921

Washington, D.C. 20006

(202) 293-3950

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25

13  
14  
15  
16  
17  
18  
19  
20  
21

22  
23  
24  
25

1 UNITED STATES OF AMERICA

2 NUCLEAR REGULATORY COMMISSION

3 \*\*\*

4 BRIEFING ON STATIC ELIMINATION PROBLEMS

5 \*\*\*

6 PUBLIC MEETING

7 \*\*\*

8 Nuclear Regulatory Commission

9 Room 1130

10 1717 H Street, Northwest

11 Washington, D.C.

12  
13 Thursday, February 18, 1988

14  
15 The Commission met in open session, pursuant to  
16 notice, at 2:10 p.m., the Honorable LANDO W. ZECH, Chairman of  
17 the Commission, presiding.

18 COMMISSIONERS PRESENT:

19 LANDO W. ZECH, Chairman of the Commission

20 THOMAS M. ROBERTS, Member of the Commission

21 FREDERICK M. BERNTHAL, Member of the Commission

22 [By telephone hook-up]

23 KENNETH CARR, Member of the Commission

24

25

## 1        STAFF AND PRESENTERS SEATED AT THE COMMISSION TABLE:

2                    J. HOYLE, Secretary

3                    W. PARLER, OGC

4                    V. STELLO, EDO

5                    DR. FRANK YOUNG, FDA

6                    R. BERNERO

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

## P R O C E E D I N G S

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

CHAIRMAN ZECH: Good afternoon, ladies and gentlemen.

Commissioner Rogers is on travel and will not be with us this afternoon. Commissioner Bernthal is ill at home, but I understand he is on a conference call. Can you hear us, Commissioner Bernthal?

COMMISSIONER BERNTHAL: Yes, but it seems to be coming in and out.

CHAIRMAN ZECH: All right.

COMMISSIONER ROBERTS: I don't know how sick you are, Fred, but I admire your devotion to duty.

[Laughter.]

CHAIRMAN ZECH: All right. And I understand also the five Regions are on, and I presume they have been checked out. Is that right, Mr. Secretary?

MR. HOYLE: Yes, sir, they have been checked out.

CHAIRMAN ZECH: All right. This afternoon's briefing is a status briefing before the Commission. The NRC staff will address the current actions being taken to address the failure of 3M static eliminator devices. On January 21st, 1988, Ashland Chemical Company reported an accident involving radioactive contamination which was traced to a static eliminator device. This device uses high velocity air passing near a polonium 210 radioactive source to ionize the air. The air is used to remove dust from containers.

1           The device is manufactured under NRC license by  
2 Minnesota Mining and Manufacturing Company. Subsequent to the  
3 Ashland Chemical report, the NRC has issued three immediately  
4 effective orders to Minnesota Mining and Manufacturing Company,  
5 one suspending distribution of these devices, and two,  
6 involving removal of these devices from use in processes that  
7 have the potential for the contamination to be consumed by or  
8 applied to humans.

9           Specifically, food, beverage, cosmetics, and  
10 pharmaceutical applications have been suspended, and the  
11 devices recalled by the manufacturer in accord with NRC orders.  
12 Two additional immediately effective orders have been prepared  
13 for issuance today. They direct the 3M Company first to  
14 suspend the use of all polonium 210 devices within 30 days.  
15 Second, recall all polonium 210 static eliminator devices to 3M  
16 within 90 days.

17           Third, to promptly test the devices for detectable  
18 radioactive leakage, and if any is detected, notify the users  
19 of the device of the potential for contamination in the  
20 workplace. And fourth, to notify the NRC or the agreement  
21 state of the leaking device.

22           A report of compliance with the order and any  
23 exceptions is also required by the orders. In cases where  
24 safety considerations exist that require the continued use of  
25 the devices, the order to the users contains a provision to

1 allow continued use with suitable monitoring under written  
2 approval from the NRC or the agreement state for the specific  
3 case. These orders are to be published in the Federal Register  
4 in approximately five working days.

5 The NRC has been and continues to work closely with  
6 the Food and Drug Administration and with the agreement states  
7 to assure that all available actions are being taken to protect  
8 the public and workers. Dr. Frank Young, Administrator of the  
9 Food and Drug Administration, is here with us today, as he was  
10 last week, when the Commission was briefed on these facilities.

11 We welcome you, Dr. Young, and we appreciate your  
12 being with us today.

13 DR. YOUNG: Thank you.

14 CHAIRMAN ZECH: I urge the staff and the FDA to  
15 continue to work together to assure that we are doing all that  
16 we can to protect health and safety.

17 Do my fellow Commissioners have any opening remarks  
18 to make?

19 [No response.]

20 CHAIRMAN ZECH: If not, Mr. Stello, you may proceed.

21 MR. STELLO: Thank you, Mr. Chairman. As you have  
22 already indicated, we are pleased to have Dr. Young with us  
23 again today, and I have Mr. Bernero with me, who has been  
24 following this essentially full-time, seven days a week, to  
25 understand the full significance of the issue that we are faced

1 with.

2 You have already indicated that you had approved an  
3 order and you described the context of that order, and it has  
4 in fact been signed, and a copy had been sent to 3M, and the  
5 remaining order -- orders will be placed in the Federal  
6 Register, as you indicated, in about five days.

7 We expect that this will be a problem that will be  
8 with us, as we indicated last time, for some time. The number  
9 of devices is large. The number of facilities where we have  
10 found contamination continues to grow. Our purpose today is to  
11 brief you on where we stand with respect to our knowledge of  
12 the problem, what we have done about it, and what more remains.

13 With that, I will turn to Mr. Bernero to give you a  
14 brief status, and that will be followed by some remarks by Dr.  
15 Young.

16 CHAIRMAN ZECH: All right. Thank you very much. Mr.  
17 Bernero, you may begin.

18 MR. BERNERO: Thank you, Mr. Chairman.

19 May I have the first slide, please?

20 [SLIDE.]

21 MR. BERNERO: I have a slide here just to refresh  
22 your memories on the licensing basis or the requirements for a  
23 generally licensed device such as we are talking about here.  
24 The regulations, and these are rather old regulations -- they  
25 go back many years. A device for general licensing has four



1 key provisions. It should be safely handled by persons who are  
2 not specifically trained in radiological safety, and under  
3 ordinary conditions, nothing should be released. The  
4 radioactive material should be closely or tightly held.

5 In addition, there are two other requirements that  
6 relate to the direct radiation in normal use and the release or  
7 dosage in case of fire. They aren't really pertinent here and  
8 I don't intend to dwell on them. The 3M license, which is a  
9 specific license authorizing general license distribution is  
10 also an old proceeding. It goes back to 1965. And I must say  
11 that in the record of the licensing as best we can understand  
12 it -- obviously, going back so many years you have different  
13 people who are no longer with us -- I think it was clear that  
14 there was an understood potential for some leakage, no barrier  
15 could be perfect if you have an adhesive of these microspheres,  
16 but it was not expected to have releases under ordinary  
17 conditions. That is the best we can interpret the entire  
18 record, although I just say there is no explicit numerical  
19 criterion on what constitutes acceptable leakage, there is no  
20 thousandth of a percent or one in a million or any number like  
21 that.

22 The license in question or licenses were expanded to  
23 multiple devices with increased reporting requirements in 1978,  
24 about a decade after they were first issued. I include a  
25 picture of the microsphere just to refresh your memories.

1 Remember, this is the key safety system where the radioactive  
2 material is tightly held in this particle so that even if it is  
3 released the public risk is not great, because the microsphere  
4 is a rather robust form, it is a little too large to be  
5 breathed, and it is also quite insoluble, and there are  
6 solubility data in the licensing record to support that.

7 May I have the next slide, please?

8 [SLIDE.]

9 MR. BERNERO: You reviewed some of the chronology. I  
10 have two slides here, Number 1 and Number 2, of chronology, and  
11 all I would like to say is, rather than go into the specifics  
12 of the order which you already summarized, I would like to  
13 characterize the thrust of the investigation. At the very  
14 beginning it appeared, since this was a chemical works and an  
15 isolated report, it appeared that we were dealing with an  
16 exceptional case, and if you read the order, if you read the  
17 record, if you were involved at all in the discussions at the  
18 time, there was an appearance of focusing on an exceptional  
19 case and as the data grew and this first chronology sheet shows  
20 more failure data coming in in the weeks following the initial  
21 report and the initial investigation, it led us to the concern  
22 toward more widespread application, but still focused on the  
23 compressed air devices.

24 The even numbered, 902, 902F, 906, and 908, are the  
25 serial numbers of the static elimination devices used with

1 compressed air, the highest velocity.

2 Still, the focus was on exceptional cases or  
3 exceptional circumstances with an alarming increase in the  
4 number. The food, beverage, cosmetic, and pharmaceutical uses,  
5 packaging, that we encountered, and we are finding failures  
6 there, that raised a concern with our sister agency, the FDA,  
7 and of course a great deal of priority given to pursue those  
8 applications, one, to find and stop the leakers, and secondly,  
9 to examine the products wherever they were actually or  
10 potentially contaminated.

11 May I have the next slide, please?

12 [SLIDE.]

13 MR. BERNERO: If you go to the second chronology, 3M,  
14 in accordance with the first order, submitted to us a letter  
15 report containing a plan on February 8th, and there was a  
16 subsequent meeting on that plan on February 11th.

17 The February 8th report had a body of data that was  
18 available to 3M apparently at that time, and their focus was on  
19 environmental causes, the situations in which the devices were  
20 being used. I will show you one of their data sheets in a  
21 moment.

22 Their plan, which I have also reproduced for your  
23 reference in a subsequent slide, was a minimal one focusing on  
24 the possible misapplication of some devices. In other words,  
25 they have a position called static analyst, a person who looks

1 at the application in the field to see that it is suitable for  
2 the device and there could have been misapplied devices, again  
3 the focus on exceptional circumstances.

4 The meeting on the 11th, we discussed those  
5 materials. The 3M top management was present. They did not  
6 have any more data to offer but they requested access to the  
7 data we had. By that time, the resources and field work being  
8 done by the NRC, by the agreement states and by the FDA, was  
9 producing a preponderance of data that was not immediately and  
10 directly available to 3M, because we were out getting it or the  
11 states were out getting it.

12 We agreed to have technical staff of the states, NRC  
13 and 3M pool this data, and that meeting is taking place  
14 tomorrow, and in discussing the plan of action, 3M agreed to  
15 submit a more detailed plan by February 26th, which is two  
16 weeks after the meeting.

17 Now, as we continued all last week, we got more and  
18 more data. Remember, the first order suspended the  
19 distribution of the compressed air devices in food, beverage,  
20 cosmetics and pharmaceutical, but did not withdraw the existing  
21 ones. What we did in order number three on February 12th, and  
22 I must say at the February 11th meeting, 3M said it was their  
23 intention to do this, we withdrew all models of all the devices  
24 from production and packaging of food, beverage, cosmetics and  
25 pharmaceutical products.

1           If you look at the next sheet, this is a table drawn  
2 directly from the 3M February 8th report, if you look at the  
3 upper cross line, bottling industry, they were analyzing by  
4 industry application, and you see a distribution of failure in  
5 bottling that seems to be significantly higher than the  
6 occasions of failure in other applications.

7           Also, if one looks at the food industry, over on the  
8 righthand side, you see 30 with a footnote "4" and 3 with a  
9 footnote "5," the data there was puzzling because there were  
10 situations where contamination was not found on the nozzle, but  
11 was found in the plant, and so there appeared to be some sort  
12 of failure patterns there.

13           Again, the focus here was on adverse environment that  
14 would be exceptional, not typical.

15           The plan that I mentioned earlier is this next slide.  
16 This is lifted verbatim from the report of February 8th by 3M.

17           [SLIDE.]

18           MR. BERNERO: You can see by perusal of it that it is  
19 fundamentally reviewing the list of distribution, improving  
20 product literature, improving static analysts' training in  
21 order to weed out exceptional causes of failure.

22           [SLIDE.]

23           MR. BERNERO: In the meanwhile, the NRC staff sent an  
24 inspection team up to 3M and gathered the data from their own  
25 records. What I have here is a table which was used in our

1 February 11th meeting. I have added a few notes to it for your  
2 information.

3 Basically, for the distribution set that was  
4 distributed in 1986, from the 1986 reports. If you look at the  
5 prices, they are broken down by model number into the brackets  
6 of compressed air use, static bars and blown air. The numbers  
7 are representative. 1987 would have been somewhat different  
8 and 1988 even different still. The basic distribution of  
9 devices is rather significant, I think.

10 Fifty-seven percent of all the devices are compressed  
11 air; 34 percent are static bars and only 8 percent are blown  
12 air.

13 From the 3M records, the next column, we found  
14 detectable leakage at the plant, at the 3M plant of these  
15 devices as listed, but as reported, the two columns on the  
16 righthand side, were data that was analyzed and then filtered  
17 in a way by saying, well, there was a damaging environment, so  
18 that accounts for the release and therefore it is not a leaking  
19 device, it is a damaged device. 3M made that distinction.

20 In addition, 3M had a procedure for sampling in the  
21 plant we found inadequate. They have since corrected it, after  
22 this inspection. As a result, one must look at the raw data in  
23 the more or less center column, the number leaking "all," that  
24 column, as equal to or greater than data, that if a proper  
25 procedure had been used, not only would the ones listed have

1 shown up as leakers but probably more. It had to do with a  
2 screening swipe that had sort of a decontaminating effect.

3 CHAIRMAN ZECH: Were we aware of this definition they  
4 were using, this criteria they were using for leaking devices  
5 as far as calling some damaged and some undamaged?

6 MR. BERNERO: Not until we did this inspection and  
7 analyzed the data that you see. They were informed of that at  
8 the time.

9 The thing to see here is when we go back to this  
10 data, which may be an under call, we see the distribution  
11 involving other model numbers and the rather interesting thing,  
12 for most of them, it is about a tenth of a percent failure rate  
13 that is reported.

14 With that, we used this list, recognizing the frailty  
15 of the data, we used this list as a source --

16 CHAIRMAN ZECH: Where do you see a tenth of a  
17 percent?

18 MR. BERNERO: The numbers in brackets, .04 percent,  
19 .7 percent and so on, those numbers represent a failure rate  
20 obtained by comparing 5 to 13,138 or 62 to 8,700.

21 CHAIRMAN ZECH: It looks to me like .9.

22 MR. BERNERO: Yes, it is between half a percent and a  
23 tenth of a percent. I just rounded it off.

24 CHAIRMAN ZECH: If it is .9, it is about one percent.

25 MR. BERNERO: Yes, it could be as high as one

1       percent. It is as low as .04 percent. Most of them are in the  
2       cluster of a half to one.

3               CHAIRMAN ZECH: Do we consider one high? That seems  
4       to me to be something we should be concerned with.

5               MR. BERNERO: The concerns that one gets looking at  
6       these data, the concerns are that in the first place, it is  
7       getting close to the failure level certainly that one would  
8       say, hey, that's too much, that can't represent ordinary  
9       conditions. It is distributed over other model numbers. It is  
10      not merely in the compressed air devices.

11              CHAIRMAN ZECH: Were we aware of these percentages,  
12      almost one percent? When were we first aware of that?

13              MR. BERNERO: I would say we found this out in the  
14      last two weeks, about a week and a half ago.

15              CHAIRMAN ZECH: Is there anything in our regulations  
16      that require a certain number as far as a leakage percentage or  
17      do we require any reports from them if it looks to them like  
18      the leakage is higher than it should be?

19              MR. BERNERO: We require reports at .005 microcuries  
20      detected activity released. That derives from the regulations.  
21      That is not the detectable level. There is no criterion either  
22      in the license or in the regulations that says what percentage  
23      of leaking devices constitutes unacceptability or  
24      acceptability.

25              CHAIRMAN ZECH: Maybe there should be.



1           MR. BERNERO: The regulations, in that first slide,  
2           the regulations just say in ordinary use, the material should  
3           not be released.

4           CHAIRMAN ZECH: Maybe there should be. I assume you  
5           will look at this.

6           MR. BERNERO: It is something we will definitely look  
7           at.

8           The other thing that I would point out as a cause for  
9           concern looking at this data is if the models are so different,  
10          than we have a lot broader problem than the focus we had at the  
11          beginning of focusing on the compressed air models and the  
12          exceptional case.

13          [SLIDE.]

14          MR. BERNERO: The next two sheets are a list that we  
15          have tried to keep available to you as we went along. It is a  
16          list of sites with failed devices. If you look at the footnote  
17          on the lower right, contamination at these facilities exceeded  
18          .005 microcuries. That is 11,000 disintegrations per minute.  
19          That's the reportability criterion in the regulations. We use  
20          it as a threshold to sort this list, although we knew there  
21          were other facilities where less than that level of  
22          contamination was detected, was found, but it was below the  
23          reported level.

24          This is an incomplete list. It changes daily. It  
25          does show, however, many diverse applications and different

1 models of the devices are involved, and what is more troubling  
2 is it shows many different, very different pathways for  
3 exposure to persons. If you go to the second page, you will  
4 see number 37, the Moto Photo Shop in North Dartmouth,  
5 Massachusetts. That occurred last Saturday. It was discovered  
6 last Saturday. This is one of these photo developing shops you  
7 find in a shopping mall.

8 Our inspectors found quite a bit of contamination  
9 leaking from the device used to cut the static on the film that  
10 was being developed. It was a compressed air model. How much  
11 of it tracked out into the mall or what is just unknown. You  
12 can see the many different pathways to man that can be seen.  
13 Of course, many of these are food, beverage, cosmetic and  
14 pharmaceutical applications.

15 CHAIRMAN ZECH: Do your orders require all these  
16 devices be recalled?

17 MR. BERNERO: Yes, they do. I am going to give you a  
18 summary of the orders.

19 CHAIRMAN ZECH: The ones on this sheet, the devices  
20 are all being recalled?

21 MR. BERNERO: Yes. They are either recalled  
22 immediately, if they are food, beverage, cosmetic and  
23 pharmaceutical, they are already recalled and that is in  
24 motion, or they are recalled by today's orders on a timeframe  
25 if they are other applications, with only a safety exclusion

1       that I will explain.

2               One other thing. I haven't even had time to type  
3       this up in a usable form. We have had telephone call-ins from  
4       the agreement states and in a rough summation of all the  
5       agreement states, they have surveyed by now 828 facilities and  
6       found detectable contamination, not reportable but detectable  
7       contamination at 118 facilities of the 828. That is  
8       approximately 15 percent. That of course, would clearly be an  
9       unacceptable level of release.

10              [SLIDE.]

11              MR. BERNERO: You may recall from a week ago when you  
12       were briefed on this, the current safety conclusion was the  
13       very thing, and I consciously used the very conclusion, because  
14       we are still holding to this conclusion. Based on the data we  
15       have at this time, even if these microspheres gained access to  
16       the workplace or to the consumer products, it is unlikely there  
17       is a significant health hazard to the public. That does not  
18       excuse us of vigorous evaluation of the potential safety  
19       significance and getting out there to find what is contaminated  
20       and to stop it.

21              In order to do that, we felt, considering the broad  
22       range of models and applications involved and the growing  
23       failure rates, the more we looked at it, the higher the failure  
24       rate appeared to be, we generated the two orders of February  
25       18th that were signed and started out this morning, and the

1 summary is there are two orders because of the parties  
2 involved.

3 We have one order as to 3M and the other order is to  
4 the general licensees using the 3M static elimination devices.  
5 In essence, the orders suspend the transfer and use of these  
6 devices, recall them to 3M for tests and appropriate use of the  
7 test results, and there is an exception in the order for  
8 competing safety risks.

9 [SLIDE.]

10 MR. BERNERO: I would summarize the orders. The 3M  
11 order, and I have tried to paraphrase the five elements of the  
12 order --

13 CHAIRMAN ZECH: You mean the order to 3M?

14 MR. BERNERO: Yes.

15 CHAIRMAN ZECH: From NRC?

16 MR. BERNERO: Yes. The order to 3M from NRC says,  
17 first of all, suspend transfer of these devices except as  
18 specifically authorized by NRC. Secondly, immediately notify  
19 the general licensees. This is the priority way for the  
20 general licensee to learn of this. They will get a copy of the  
21 orders through 3M in this order clause.

22 Third, instruct the users to return the devices, you  
23 know, the packaging and things like that, identification, as  
24 soon as feasible but no more than 90 days from the date of the  
25 order.

1           Fourth, 3M will test the returned devices for  
2     leakages, one of the important pieces of data, which may  
3     indicate contamination out there in the field that needs to be  
4     found, and therefore, the results of the tests where leakage is  
5     found, detectable leakage, notify the user who sent the device  
6     in, the NRC and the affected agreement state.

7           Lastly, provide status reports on the progress in  
8     doing this at 30 day intervals.

9           In addition, this order, and I separated it here, is  
10    a show cause order. It is an instruction to 3M to show cause  
11    in 60 days why this license shouldn't simply be revoked, and  
12    then just proceed with the clean-up.

13          The corollary order to the general licensees, and  
14    this is under our regulations, to them, we order suspend the  
15    use of the devices. Secondly, send the devices back to 3M  
16    within the 90 days, and thirdly, we do leave a loophole, if you  
17    will, temporary continuation of use is possible where it is  
18    essential for safety. This is fire, explosion or other  
19    hazards, in order to suppress it. It would require written  
20    approval of the NRC or the agreement state involved and it  
21    would be under surveillance to be specified by them. That  
22    would be unique to the application. That exception does not  
23    apply to food, beverage, cosmetic, pharmaceutical or medical  
24    devices. It applies only to what we would call industrial or  
25    commercial applications.

1                   COMMISSIONER ROBERTS: Who makes the call on the  
2 first element of essential for safety?

3                   MR. BERNERO: The user says, I need it, and has to  
4 ask for permission. The order is written to have the affected  
5 regional administrator or the affected agreement state  
6 authority make the call of whether it is acceptable and the  
7 conditions under which it would be acceptable.

8                   Note, it is temporary and it would give an  
9 opportunity for alternative courses to be sought, and of  
10 course, the time period can be controlled that way.

11                   Keep in mind, the half life of these devices, the  
12 half life of the isotope, is relatively short, so that the  
13 isotope drops in radioactivity level by approximately a factor  
14 of six in one year.

15                   CHAIRMAN ZECH: A half life is what?

16                   MR. BERNERO: 138 days. It really decays rather  
17 substantially in a year.

18                   This order is also published in the Federal Register.  
19 That is the formal way to promulgate it, but the expeditious  
20 distribution of it is through the order to 3M.

21                   CHAIRMAN ZECH: Which we have done?

22                   MR. BERNERO: Yes, that's the fastest way to get it  
23 to all.

24                   That's the summary. I would like to turn it over  
25 now.

1           MR. STELLO: Mr. Chairman, with your permission, I  
2 will turn to Dr. Young for one comment, but I don't know that  
3 the presentation was clear and I would like to make sure it is.

4           This order is immediately effective. These devices  
5 are cease and desist now. The timing of the issues are more  
6 with respect to the timing to be returned to 3M.

7           CHAIRMAN ZECH: I was going to ask about the 30 and  
8 90 days. It is immediately effective?

9           MR. BERNERO: Yes, to summarize, the food, beverage,  
10 cosmetic and pharmaceutical devices are already under order for  
11 return by, I believe, it is March 2nd. That is in progress.  
12 That is going on right now.

13           This order recognizes that. It is explicitly  
14 recognized. Then what we are dealing with are the rest of the  
15 devices, what I call commercial and industrial. Those have as  
16 soon as feasible but not longer than 90 days.

17           CHAIRMAN ZECH: To do what?

18           MR. BERNERO: To return them. It says cease  
19 immediately. Of course, that is going to be a variable time  
20 depending on when the individual licensee got the word and so  
21 forth.

22           [Commissioner Roberts left the room at 2:40 p.m.]

23           CHAIRMAN ZECH: We have given orders now to cease and  
24 desist their use.

25           MR. BERNERO: Yes.

1 MR. STELLO: Effective immediately.

2 CHAIRMAN ZECH: Of not only the food and drug type,  
3 pharmaceutical, cosmetic devices, but all the others also?

4 MR. BERNERO: All models, all applications.

5 CHAIRMAN ZECH: All models, all applications of these  
6 devices. The order calls for them to cease with their use  
7 immediately and to recall them; is that correct?

8 MR. STELLO: That is correct.

9 DR. YOUNG: First of all, Mr. Chairman, I want to  
10 thank your staff for the very thorough interaction with our  
11 staff and the cooperation that you have given us in the ability  
12 to fulfill our mission.

13 CHAIRMAN ZECH: I appreciate that.

14 DR. YOUNG: They have done a tremendous job, and I  
15 know they have been working around the clock on it.

16 CHAIRMAN ZECH: I know they have been working very  
17 hard, and I appreciate what you and your people have been  
18 doing, too, Doctor. This is our joint responsibility.

19 DR. YOUNG: Yes, it is.

20 CHAIRMAN ZECH: And we want to make sure that you get  
21 the continued cooperation of our staff. If you don't, please  
22 let me know.

23 DR. YOUNG: They have been very cooperative. And I  
24 also fully support your action that is taken to remove these  
25 from the marketplace. I think that's particularly relevant,



1 because I do have a letter that I know the 3M Company sent out  
2 as of February 15th, '88, that said if firms believed that the  
3 device was imperative for continued use, to contact FDA for  
4 approval for that continued use, and I want to state for the  
5 record that we fully support your action that no approval of  
6 such continuation should be provided.

7 We have done the following things since our last  
8 meeting:

9 First of all, we have inspected each of the 16 firms  
10 that have now been identified, 13 plus the original ones that  
11 were on, and have collected samples from 13 of these and  
12 completed most of the analyses.

13 Altogether, we have analyzed over 1300 samples, and  
14 we will continue to have our Winchester Laboratory working a  
15 two 12-hour shift to deal with this.

16 We have also divided our products into those that  
17 might present a risk and have looked at those first, and then  
18 followed up on others that we would think would be less risky.

19 For example, we were looking first at devices that  
20 were in things such as nasal sprays or anything that would go  
21 directly into the body, in contrast to lotions or creams, where  
22 we know that the penetration of the skin would be low.

23 We have looked, as your lists have provided, and  
24 found about 263 firms that do fall within the Food, Drug and  
25 Cosmetic Act that are either producing drugs, biologics,

1 devices, cosmetics or foods.

2 Of these, we have found in your plants that had  
3 detectable radiation above the limit no samples that were  
4 positive.

5 We have found one fragment of a microsphere in one of  
6 the plants that you had detectable activity, but not above the  
7 background, and this was very helpful again to have your total  
8 list of those that have any detectable activity.

9 We are going to take the strategy of looking at all  
10 of these firms first with those that were detectable and out of  
11 compliance. We have found no evidence of contaminated product  
12 there. Detectable but not out of compliance, as you define it,  
13 and then all other plants. And we will look in that fashion.

14 We continue to believe, as you have pointed out, from  
15 our analyses that there is no evidence of any public health  
16 hazard at this time and no hazard to health. Even in the event  
17 that an entire microsphere were ingested or an entire  
18 microsphere were inhaled, we do not believe, based on the  
19 calculations and the calculations that we have received from  
20 your agency, lead us to feel very strongly that there would not  
21 be a health hazard. And I think the important thing for the  
22 American people to realize is that although we are out and  
23 going to inspect all of the plants, and though we will examine  
24 the samples, we are doing this to provide an extra layer of  
25 safety so that we can be sure that there is not that rare gun

1 out there that may be leaking more than we would anticipate.

2 We are very comfortable at this time, based on the  
3 evidence that we have, that there is neither a hazard to public  
4 health or a hazard to individual health.

5 CHAIRMAN ZECH: Thank you very much, Doctor. Does  
6 that complete --

7 MR. STELLO: That completes our presentation, Mr.  
8 Chairman.

9 CHAIRMAN ZECH: All right. I will ask for comments  
10 from my fellow Commissioners. Commissioner Roberts had to  
11 leave for a few moments for a previous appointment.

12 Commissioner Carr, do you have any questions?

13 COMMISSIONER CARR: No.

14 CHAIRMAN ZECH: Commissioner Bernthal, I know you are  
15 on. I hope you have been able to hear us all right. Do you  
16 have any questions?

17 COMMISSIONER BERNTHAL: No, I don't. I think I got  
18 about 75 percent of it.

19 CHAIRMAN ZECH: All right.

20 Well, let me ask a couple.

21 First of all, what is the total number of devices  
22 that we have that we are talking about? Do we know, the total  
23 number of devices?

24 MR. BERNERO: Well, if you use the chart that I had  
25 to show the distribution of models, in 1986, it was

1 approximately 42,000 devices, and the current number is  
2 probably not too far from that. I don't know the exact number,  
3 but that's a reasonable figure for the total. And the  
4 breakdown of them is on that chart that I used where they are  
5 broken down into compressed air, static bars and blown air.

6 CHAIRMAN ZECH: Now, that's the total number, 42,000?

7 MR. BERNERO: 42,000 devices, units, and they are all

8 --

9 CHAIRMAN ZECH: Of all kinds?

10 MR. BERNERO: All kinds; all forms, all model

11 numbers.

12 CHAIRMAN ZECH: All right. I have been told that  
13 there is another manufacturer of similar devices, and that a  
14 site visit was scheduled for last week, I think that's correct.  
15 What was the result of that visit? And is the Staff sure that  
16 we don't have a similar situation with that licensee?

17 MR. BERNERO: Okay, that staff visit was made. It's  
18 actually a New York State licensee. The New York State  
19 licensee uses a somewhat different technology.

20 CHAIRMAN ZECH: Is it a different manufacturer than  
21 3M?

22 MR. BERNERO: Yes, it's a different company,  
23 different manufacturer, and a different way of doing it.

24 CHAIRMAN ZECH: How many devices have they got?

25 MR. BERNERO: If I remember the number, it's

1 approximately 1500, a little bit over --

2 CHAIRMAN ZECH: Is that included in the 42,000?

3 MR. BERNERO: No, no. This is --

4 CHAIRMAN ZECH: These are in addition?

5 MR. BERNERO: These are polonium-210, but they have  
6 gold foil, it's not a microsphere --

7 CHAIRMAN ZECH: Are we examining those?

8 MR. BERNERO: They have been looked at, and the State  
9 of New York -- apparently they are distributed only in New  
10 York, and that is an agreement state. But our staff has been  
11 out there, has looked at the devices. There is no evidence of  
12 failure in those devices.

13 There is another supplier that is an NRC licensee in  
14 California that we are tracking down now that is licensed to  
15 make static eliminators using polonium-210 of a much, much  
16 smaller size, at least an order of magnitude smaller in size.  
17 They are things like static brushes for --

18 CHAIRMAN ZECH: But we are contacting that  
19 manufacturer?

20 MR. BERNERO: Yes, we are contacting them to see what  
21 --

22 CHAIRMAN ZECH: Have we contacted them yet?

23 MR. BERNERO: I can't say that for sure. We're  
24 working through Region V.

25 CHAIRMAN ZECH: Region V, are you on the phone? Do

1       you know?

2               MR. BERNERO: An important feature there is it's a  
3 significantly smaller device to begin with. The inventory of  
4 radioactive material in it is at least an order of magnitude  
5 smaller.

6               CHAIRMAN ZECH: But that is another manufacturer  
7 other than the 3M and the New York --

8               MR. BERNERO: Yes.

9               CHAIRMAN ZECH: How many more do we have?

10              MR. BERNERO: We know of no others.

11              CHAIRMAN ZECH: I see. Well, let's find out if  
12 they've been contacted. If not, contact them as soon as  
13 possible.

14              MR. BERNERO: Absolutely. We are tracking that down.

15              CHAIRMAN ZECH: And I presume that we are going to do  
16 an inspection of that firm also.

17              MR. BERNERO: Yes, indeed.

18              We believe California is inspecting -- see,  
19 California is an agreement state, and we believe California is  
20 inspecting. We don't have their report yet, but California is  
21 one of the states participating in this meeting tomorrow. The  
22 five states are participating, in my last news, and they are  
23 all major user states -- that is, California, Illinois, Florida  
24 -- oh, I forget the other two, but states with a large  
25 inventory of these devices.

1 REGION V SPEAKER: You made a comment a moment ago  
2 about the facility out here in California.

3 CHAIRMAN ZECH: Yes, Region V, go ahead.

4 REGION V SPEAKER: You were making reference to  
5 neutron products which is in the local area here. We had a  
6 call yesterday from Steve Baggott to send the complete license  
7 file back to him, which is being done today. The inspection on  
8 this -- they have been inspected four times over the last two  
9 years, and they have always had a clean inspection. They have  
10 nothing in the way of a bad enforcement history or inspection  
11 history on those people.

12 CHAIRMAN ZECH: All four inspections, you say, were  
13 clean inspections? That means you detected nothing improper,  
14 no problem with our regulations?

15 REGION V SPEAKER: That's right. They were clear  
16 inspections.

17 CHAIRMAN ZECH: All right. Clear inspections. All  
18 right. Thank you very much.

19 Dr. Young, perhaps you could help me with this one.  
20 On the solubility of polonium microspheres, if they were  
21 ingested or inhaled or otherwise taken into the body, do we  
22 have any indication that they would be soluble, and if so, what  
23 would be the result?

24 DR. YOUNG: The microspheres have been studied both  
25 commercially and in laboratory animals. The only area that we

1 think would be any problem would be in the hydrochloric acid  
2 in the stomach. Based on the information that your agency  
3 provided in regards to acid solubility, we are looking at below  
4 a tenth of a percent leaching from this in months.

5 CHAIRMAN ZECH: What would that do to the human body?

6 DR. YOUNG: That would essentially be negligible.

7 There should not be any detectable radioactivity that would be  
8 released in the -- the result is insignificant.

9 CHAIRMAN ZECH: All right.

10 MR. BERNERO: I might add to that, Mr. Chairman, we  
11 also have some results from our own lab in Idaho, where they  
12 have taken pristine microspheres and done solution tests for 40  
13 hours in Coca Cola and beer, and have found negligible  
14 solubility.

15 CHAIRMAN ZECH: I see. Are we still doing more of  
16 those tests now?

17 MR. BERNERO: Yes. More tests are going on, I  
18 believe.

19 CHAIRMAN ZECH: And Dr. Young, are you involved in  
20 those tests, too?

21 DR. YOUNG: No, that is being done in your  
22 laboratories, but we rely very heavily on the work that's been  
23 done with concentrated hydrochloric acid, since that study has  
24 shown that there is less than a tenth of a percent of  
25 solubility.



1 CHAIRMAN ZECH: Well, we are providing the FDA with  
2 the --

3 MR. BERNERO: Yes. The FDA has the information. The  
4 licensing basis of this device, the microsphere, included  
5 extensive solubility data and that included hydrochloric acid  
6 stronger than beverages --

7 DR. YOUNG: I think we used 6 normal or something  
8 like that.

9 MR. BERNERO: A hundred normal. It's a pH of 2. And  
10 that is pretty acid. You wouldn't have a very good stomach if  
11 you --

12 DR. YOUNG: I think there is not a problem from what  
13 we can see from the work that was done as part of your license.

14 CHAIRMAN ZECH: All right.

15 DR. YOUNG: The ability to -- and also it should be  
16 emphasized that transit time for this going from the mouth out  
17 into the feces is probably on the order of two to four days.  
18 So it's not going to reside any period of time, and with that  
19 very low dissolution rate, it's a negligible risk.

20 CHAIRMAN ZECH: All right. Just to make sure that I  
21 am clear on all this, do our orders that we have got out that  
22 are currently drafted or have been issued cover all of the  
23 polonium-210 static eliminator devices that have been  
24 distributed by any licensee that we are aware of?

25 MR. BERNERO: No. They cover only the polonium-210

1 static elimination devices that 3M has distributed under the  
2 NRC license. They do not apply to this company in California  
3 that Region V just spoke of, and they do not apply to the  
4 polonium-210 devices that I mentioned the New York company has.

5 CHAIRMAN ZECH: All right. But I presume that as you  
6 are investigating those companies --

7 MR. BERNERO: Yes, certainly.

8 CHAIRMAN ZECH: -- if you find any need to put out a  
9 similar order, you will do so?

10 MR. STELLO: Excuse me, Mr. Chairman. You recall  
11 both of those companies are in agreement states?

12 CHAIRMAN ZECH: Yes, I understand that.

13 MR. STELLO: The orders would --

14 CHAIRMAN ZECH: But we'd make sure that --

15 MR. BERNERO: Except through an administrative  
16 peculiarity, the California one is actually an NRC license.

17 CHAIRMAN ZECH: All right. Well, in any case, we  
18 want to make sure that we have covered all the bases.

19 MR. BERNERO: We are following up with vigor to make  
20 sure that we have all of the bases and we are also looking at  
21 the other potentially relatable licenses.

22 CHAIRMAN ZECH: And how about the possibility of any  
23 of these devices being exported to other countries?

24 MR. BERNERO: What we have done, in the -- it gets  
25 kind of tricky, because under our regulations, Part 1.10

1 authorizes export. Now what we did in the order to 3M, we  
2 directed 3M not only to report to the users about these orders  
3 -- you know, to send these orders to the users, but to send  
4 them to the international distributors. So that the  
5 information is there. It gets a little trickier if you want to  
6 now take action against the user in a foreign country.

7 MR. PARLER: It does get tricky. We have no  
8 jurisdiction over the use in a foreign country that I know  
9 about.

10 [Laughter.]

11 MR. PARLER: But we can tell the international  
12 community, the IAEA, about the problem, et cetera, et cetera.  
13 We can seek cooperation, but we have no jurisdiction that I am  
14 aware of outside of our borders.

15 CHAIRMAN ZECH: But we should certainly inform them.

16 MR. BERNERO: Except the FDA has a concern.

17 MR. PARLER: I was thinking just about the Nuclear  
18 Regulatory Commission, under the Atomic Energy Act and Energy  
19 Reorganization Act.

20 DR. YOUNG: Mr. Chairman, we would be able to reach  
21 that from our regulatory mode. And what we have done is the  
22 following two things:

23 We have notified the State Department so that we  
24 could work through this and have that through the networks, and  
25 then we are beginning through our network of other regulatory

1 agencies in the countries that we would identify as we get  
2 information from either 3M or NRC, we will use our networks to  
3 let those countries know of the problems that we have. So that  
4 is already underway. That's a significant issue, because we  
5 can't just rest on the United States territory. We have to  
6 look at the other parts of the world.

7 I might also add on another issue, when FDA does its  
8 analyses, in addition to doing ours, the way our system works  
9 is we require the company who has been the consignee or whom  
10 this device has been sold to, to do a large number of assays,  
11 and then our assays are done as a check against the corporate  
12 assays.

13 So many, many more assays have been done beyond the  
14 1300 that I mentioned earlier.

15 CHAIRMAN ZECH: All right, fine.

16 DR. YOUNG: So that we are continuing to look to make  
17 sure there is no safety problem. We don't see anything here at  
18 this point.

19 CHAIRMAN ZECH: Okay, fine. Well, I think whatever  
20 we come up with here, too, would be certainly of great interest  
21 to the International Atomic Energy Association, and I think we  
22 should at least keep them informed, and I presume that we  
23 intend to do that.

24 MR. STELLO: Yes, sir.

25 CHAIRMAN ZECH: Okay.

1 Are there any other questions? Commissioner Carr?  
2 Commissioner Bernthal, do you have any before we  
3 conclude?

4 All right. If not, we understand that the health  
5 threat in this case is low, as we have been told several times.

6 DR. YOUNG: That is correct.

7 CHAIRMAN ZECH: Especially since the polonium is  
8 tightly bound in the microspheres and it's certainly unlikely  
9 to result in an appreciable exposure to anyone, even in the  
10 probable event that someone were to ingest them.

11 DR. YOUNG: That's correct.

12 CHAIRMAN ZECH: I presume that's what we are saying.

13 However, it seems to me that even recognizing this,  
14 that we have a responsibility to do all we can within our  
15 authority to assure that these devices do not pose any hazard  
16 to the public or to workers.

17 DR. YOUNG: That's correct.

18 [Commissioner Roberts entered the room at 2:58.]

19 CHAIRMAN ZECH: And I again certainly urge the Staff  
20 to work very closely with the FDA, and with our agreement  
21 states, to follow up aggressively on any and all leads to  
22 assure that we are doing all we can to protect the public  
23 health and safety.

24 We certainly expect that the Staff will continue to  
25 keep the Commission fully informed of all the actions that are

1 taken on this particular matter.

2 Are there any other questions?

3 Commissioner Roberts, do you have anything before we  
4 conclude?

5 All right. Well, thank you very much for a very fine  
6 briefing. Dr. Young, thank you for being with us.

7 DR. YOUNG: Thank you.

8 CHAIRMAN ZECH: We stand adjourned.

9 [Whereupon, at 3:00 o'clock p.m., the meeting was  
10 adjourned.]

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

1  
2 REPORTER'S CERTIFICATE  
3

4 This is to certify that the attached events of a  
5 meeting of the U.S. Nuclear Regulatory Commission entitled:  
6

7 TITLE OF MEETING: Briefing on Static Elimination Problems

8 PLACE OF MEETING: Washington, D.C.

9 DATE OF MEETING: Thursday, February 18, 1988  
10

11 were held as herein appears, and that this is the original  
12 transcript thereof for the file of the Commission taken  
13 stenographically by me, thereafter reduced to typewriting by  
14 me or under the direction of the court reporting company, and  
15 that the transcript is a true and accurate record of the  
16 foregoing events.  
17

18   
-----  
Ann Riley  
19  
20  
21

22 Ann Riley & Associates, Ltd.  
23  
24  
25

BRIEFING ON  
STATUS OF  
PO-210 STATIC ELIMINATOR  
ACTIVITIES

---

FEBRUARY 18, 1988

---



## BASIS FOR GENERAL LICENSE - STATIC ELIMINATORS


### 10 CFR 32.51

- ° DEVICE CAN BE SAFELY HANDLED BY PERSONS NOT HAVING RADIOLOGICAL PROTECTION TRAINING
- AND
- ° UNDER ORDINARY CONDITIONS OF USE, RADIOACTIVE MATERIAL WILL NOT BE RELEASED
- AND
- ° PERSONS WILL NOT BE EXPOSED EXTERNALLY IN EXCESS OF 10 PERCENT NRC LIMITS (PART 20)
- AND
- ° UNDER ACCIDENT CONDITIONS, UNLIKELY TO CAUSE INTERNAL AND EXTERNAL PERSON DOSE IN EXCESS OF NRC LIMITS (PART 32)

### 3M LICENSE

- ° ORIGINALLY ISSUED IN 1965
  - UNDERSTOOD POTENTIAL FOR LEAKAGE, NOT UNDER ORDINARY CONDITIONS
- ° LICENSE EXPANDED TO MULTIPLE DEVICES
  - INCREASED REPORTING REQUIREMENTS SINCE 1978

# MICROSPHERE



3M CHRONOLOGY - 1

- ° JAN. 21 ASHLAND CHEMICAL CO. REPORT
- ° JAN. 22 NRC AT EASTON PLANT
- ° JAN. 25 ORDER #1
  - A. SUSPEND DISTRIBUTION OF 902, 902F, 906, AND 908
  - B. INFORM USERS/REMINDER OF NOTICE REQUIREMENTS
  - C. SEND COPY OF INFO. NOTICE (B) TO RA-III
  - D. TEST DEVICES AND SUBMIT PLAN BY FEB. 8
  - E. ANALYZE CAUSES
- ° JAN. 22 - FEB. 5 MORE FAILURE DATA RECEIVED
- ° FEB. 5 ORDER #2 (CONFIRMATORY)  
REMOVE 902, 902F, 906, AND 908 FROM FBCP PACKAGING

## 3M CHRONOLOGY - 2

- ° FEB. 8 3M REPORT AND "PLAN"
  - VERY LITTLE DATA
  - FOCUS ON ENVIRONMENTAL CAUSES
  - MINIMAL PLAN
- ° FEB. 11 3M/NRC/FDA MEETING AT R-III
  - 3M TOP MANAGEMENT PRESENT
  - VERY LITTLE MORE FROM 3M EXCEPT DECISION ON ALL MODELS IN FBCP AND NEED YOUR DATA
  - NRC FOCUS ON WHETHER THIS EVIDENCE SHOWS THAT ALL DEVICES ARE NOT GENERALLY LICENSABLE
  - FDA FOCUS ON FBCP PRODUCT SAMPLING AFTER REMOVAL
  - AGREED TO FEB. 19 3M/NRC/STATES MEETING AT 3M TO POOL DATA
  - 3M AGREED TO SUBMIT ACTION PLAN BY FEB. 26
- ° FEB. 5 - FEB. 12 MORE FAILURE DATA OTHER MODELS
- ° FEB. 12 ORDER #3
  - REMOVE ALL MODELS FROM FBCP PRODUCTION AND PACKAGING

TABLE A

Page 1

3M MODEL 902, 902F, 906 and 908  
STATIC ELIMINATOR  
TEST DATA

Industry Category	902		902F		906		908		(1)
	Pass	Fail	Pass	Fail	Pass	Fail	Pass	Fail	
Bottling	-	-	-	-	14	12	16	9	
Cosmetics	-	-	-	-	23	1	-	-	
Electronics	89	1	220	3	93	0	53	0	
Food	2	0	-	-	30(4)	-	3(5)	-	
Medical	36	0	-	-	2	0	14	0	
Photographic	42	0	-	-	33	1	28	0	
Paper	3	0	1	0	3	0	-	-	
Printing	26	0	-	-	33	0	9	0	
Other(6)	17	1	2	0	52	0	6	1	
Totals	215	2	223	3	283(2)	14	129(3)	10	

3M PLAN - FEBRUARY 8, 1988

BASED ON THE FINDINGS OF THIS STUDY, 3M INTENDS TO TAKE THE FOLLOWING ACTIONS:

1. REVIEW THE LIST OF DEVICES THAT WERE RETURNED IN 1987 AND HAVE TRAINED AND SUITABLY EQUIPPED STATIC ANALYSTS VISIT CUSTOMER SITES WHERE TESTING OF THE RETURNED DEVICES INDICATES POTENTIAL PROBLEMS.
2. REVISE THE PRODUCT LITERATURE TO REINFORCE THE WORDING REGARDING THE TYPE OF ENVIRONMENT WHICH MUST BE MAINTAINED TO PREVENT FAILURES.
3. PROVIDE REFRESHER TRAINING TO STATIC ANALYSTS TO BE CERTAIN THAT CUSTOMER APPLICATIONS ARE THOROUGHLY EVALUATED BEFORE LEASES ARE SIGNED. 3M WILL CONTACT THE CUSTOMER BEFORE LEASES ARE RENEWED TO BE CERTAIN THE APPLICATION HAS NOT CHANGED.

Data on Returned Devices

	<u>Model</u>	<u>No. Returned 1986</u>		<u>From 3M Records No. Leaking (All) 1986</u>	<u>From 3M Reports*</u> <u>No. Leaking</u> <u>(Undamaged) (Damaged)</u>	
Compressed Air	902/902F	13,138		5 (0.04%)	0	1
	906	8,718		62 (0.7%)	8	0
	908	<u>1,990</u>		17 (0.8%)	0	0
		<u>23,846</u>	57%			
Static Bars	315/210/220	11,050		95 (0.9%)	17	7
	203	93		0	0	0
	204	787		7 (0.9%)	0	0
	205	2,292		0	0	0
	206	<u>175</u>		1 (0.5%)	0	0
		<u>14,397</u>	34%			
Blown Air	905	2,070		0	0	0
	907	668		5 (0.8%)	0	0
	909	<u>808</u>		0	0	0
		<u>3,546</u>	8%			
		<u>41,789</u>				

\*Data from 1985 and 1986 Reports

February 17, 1988

LIST OF SITES WITH FAILED DEVICES+

COMPANY	LOCATION	TYPE OF PRODUCT	PRODUCT TEST RESULTS
1. KTI	Carrollton, TX	chemicals	-o-Pos
2. KTI	Sunnyvale, CA	chemicals	
3. Xicor	Milpitas, CA	chemicals	
4. Coca Cola	Dallas, TX	beverage	-*-NDA, -o-NDA
5. Coca Cola	Dallas, TX	beverage	-*-NDA, -o-NDA
6. Coca Cola	Fort Worth, TX	beverage	-NDA, o-NDA
7. Coca Cola	Needham, MA	beverage	-NDA
8. Anheuser Busch	St. Louis, MO	beverage	-*-NDA #-NDA
9. Custom Photo	Austin, TX	Film	-o-Pos, 20,000cpm
10. Ashland Chemical	Easton, PA	chemicals	-o-NDA
11. Ashland Chemical	Dallas, TX	chemicals	-o-Pos, 200PCi/l
12. McDonnell Douglas	St. Louis, MO	--	
13. Block Drugs	Dayton, NJ	denture adhesive	-*-NDA
14. Ford Motor Co.	Milan, MI	--	
15. Anheuser Busch	Jacksonville, FL	beverage	
16. Avon	Morton Grove, IL	cosmetics	
17. Ross Labs Div. of Abbott Labs.	Casa Grande, AZ	food, similac	-*-NDA
18. Coca Cola	Phoenix, AZ	beverage	-*-NDA -#-NDA
19. Paul Flum Ideas	St. Louis, MO	--	
20. Best Food Unit	Argo, IL	--	
21. 3M	Ames, IA	--	
22. Pepsi Cola	Tulsa, OK	beverage	-#-NDA
23. Coca Cola	San Leandro, CA	beverage	
24. Block Drug (Reedoo)	Humacao, PR	shampoo	
25. CREST Photo Labs.	Pawtucket, RI	developing	
26. South Atlantic Canners (Coke)	Bishopville, SC	beverage	
27. Photo Finish	McColl, SC	developing	

Pos= Positive Results

NDA= NO DETECTABLE ACTIVITY

-o- Test performed by Agreement States  
or General Licensee Contractors

\*= Test performed by FDA

#= Test performed by Medi Trace Labs.

+ Contamination at these facilities exceeded 0.005 uCi - 11,000 DPM



February 17, 1988

LIST OF SITES WITH FAILED DEVICES+

<u>COMPANY</u>	<u>LOCATION</u>	<u>TYPE OF PRODUCT</u>	<u>PRODUCT TEST RESULTS</u>
28. Hygeia Coca Cola	Pensacola, FL	beverage	
29. Ford Motor Co.	Utica, MI	paint	
30. Dial Corp	Ft. Madison, IA	microwave lunch packages	
31. Pro Corp	Florence, MA	plastic cases used on PC's	
32. K-Mart	Garland, TX	process film	
33. Xerox Corp	Richardson, TX		
34. Micro Technology	Boise, MD	electronic chips	
35. Miller Container	Milan, IL		
36. McLaughlin Body Co.	E. Moline, IL		
37. Moto Photo	North Dartmouth, MA	film	
38. Ross Laboratories	Alta Vista, VA	food supplement	*Pos, 222,000 dpm (1 microsphere)
39. Super Photo	New Orleans, LA	developing	

Pos= Positive Results

NDA= NO DETECTABLE ACTIVITY

o- Test performed by Agreement States  
or General Licensee Contractors

\*= Test performed by FDA

#= Test performed by Medi Trace Labs.

+ Contamination at these facilities exceeded 0.005 uCi - 11,000 DPM

### CURRENT SAFETY CONCLUSION

BASED ON THE ANALYSES AVAILABLE AT THIS TIME, EVEN IF MICROSPHERES GAINED ACCESS TO CONSUMER PRODUCTS, IT IS UNLIKELY THAT THERE WOULD BE A SIGNIFICANT HEALTH HAZARD TO THE PUBLIC. NEVERTHELESS, IN ORDER TO MORE FULLY EVALUATE THE POTENTIAL SAFETY SIGNIFICANCE, SAMPLES OF CONSUMER PRODUCTS RESULTING FROM THESE MANUFACTURING PROCESSES ARE BEING ANALYZED BY NRC AND FDA.

FEBRUARY 18, 1988 ORDERS

- ° TWO ORDERS
  - TO 3M
  - TO GENERAL LICENSEES
- ° SUSPEND TRANSFER AND USE
- ° RETURN TO 3M FOR TEST
- ° EXCEPTIONS FOR SAFETY

3M ORDER

- A. SUSPEND TRANSFER OF DEVICES
- B. IMMEDIATELY NOTIFY GENERAL LICENSEES
  - DISTRIBUTE GL ORDER
- C. INSTRUCT USERS TO RETURN DEVICES
  - ASAF BUT NO MORE THAN 90 DAYS
- D. TEST RETURNED DEVICES FOR LEAKAGE
  - NOTIFY USER, NRC, STATES
- E. STATUS REPORTS (30-DAY)

---

SHOW CAUSE IN 60 DAYS WHY LICENSE SHOULD NOT BE REVOKED

GL ORDER

- A. SUSPEND USE OF DEVICES
  - B. SEND DEVICES BACK TO 3M
    - WITHIN 90 DAYS
  - C. TEMPORARY CONTINUATION OF USE POSSIBLE
    - ESSENTIAL FOR SAFETY
    - WRITTEN APPROVAL OF NRC OR STATE
    - UNDER SURVEILLANCE TO BE SPECIFIED
    - NOT FOR FBCP OR MEDICAL DEVICES
- 
- ° PUBLISHED IN FEDERAL REGISTER
  - ° DISTRIBUTED UNDER ORDER TO 3M